Currently, the phase Ib DESTINY-Lung03 clinical study exploring the clinical efficacy of T-DXd combined with durvalumab and chemotherapy in newly diagnosed HER2-positive advanced NSCLC patients is ongoing. Here, ERBB2 is linked to non-small cell lung carcinoma.